Simulations Plus, Inc. (SLP) - What Are Investment Firms Saying About This Stock?

Key Points

• Simulations Plus has a “Reduce” consensus rating from eight brokerages: one recommends selling and seven recommend holding. The average 12-month price target is $17.25.
• SLP shares opened at $18.50, with a market capitalization of approximately $374 million and a price-to-earnings ratio of 46.25. The stock has traded between $11.09 and $21.01 over the past year.
• Institutional investors own 78.08% of the company, with several hedge funds increasing or initiating positions during the second quarter.

Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) has earned a consensus recommendation of "Reduce" from the eight brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a hold recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $17.25.

SLP has been the topic of a number of research analyst reports. BTIG Research reissued a "neutral" rating on shares of Simulations Plus in a research report on Wednesday, October 7th. Weiss Ratings restated a "sell (d+)" rating on shares of Simulations Plus in a report on Tuesday, October 6th.

Simulations Plus Price Performance

Shares of SLP stock opened at $18.50 on Tuesday. The firm has a market capitalization of $374.16 million, a price-to-earnings ratio of 46.25 and a beta of 1.31. The stock has a fifty day moving average of $18.43 and a 200 day moving average of $17.05. Simulations Plus has a 52 week low of $11.09 and a 52 week high of $21.01.

Hedge Funds Weigh In On Simulations Plus

Hedge funds and other institutional investors have recently modified their holdings of the stock. First Light Asset Management LLC raised its position in shares of Simulations Plus by 6.1% in the 2nd quarter. First Light Asset Management LLC now owns 2,792,677 shares of the technology company's stock worth $51,134,000 after acquiring an additional 159,854 shares in the last quarter. Meros Investment Management LP purchased a new position in shares of Simulations Plus in the 2nd quarter valued at approximately $2,384,493. Polar Asset Management Partners Inc. purchased a new position in shares of Simulations Plus in the 2nd quarter valued at approximately $2,341,000. Groupe la Francaise bought a new stake in shares of Simulations Plus during the second quarter valued at approximately $2,329,000. Finally, Bank of America Corp DE bought a new stake in shares of Simulations Plus during the second quarter valued at approximately $1,754,000. Hedge funds and other institutional investors own 78.08% of the company's stock.

About Simulations Plus

Simulations Plus, Inc develops software and provides services that support pharmaceutical research, drug development and regulatory decision-making. Its technologies help scientists model how drug compounds behave in the body, assess formulation and delivery characteristics, and evaluate potential safety and efficacy outcomes.

The company's software portfolio includes GastroPlus, a platform for physiologically based pharmacokinetic and pharmacodynamic modeling; ADMET Predictor, which forecasts absorption, distribution, metabolism, excretion and toxicity properties; and DDDPlus, which simulates drug dissolution and dosage-form performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.